Several companies are developing drugs that target the protein lipoprotein (a), associated with cardiovascular disease, with AstraZeneca paying $100 million to license a preclinical drug from CSPC Pharmaceutical Group. This drug, YS2302018, is an oral disruptor of Lp(a) and has the potential to be a competitor to other therapies targeting PCSK9. AstraZeneca’s cardiovascular drug lineup includes Farxiga and Brilinta, and they are currently testing the CSPC drug in combination with their own PCSK9 inhibitor. Analysts believe that upcoming data presentations could shape the landscape of potential cardiovascular therapies, with a focus on Lp(a) and PCSK9 inhibition combinations.
Source link
AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for Oral Way to Drug Lp(a)
